[HTML][HTML] The evolution of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …
[HTML][HTML] Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer
MA Rice, SV Malhotra, T Stoyanova - Frontiers in oncology, 2019 - frontiersin.org
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Y Duan, H Zhou, X Liu, S Iketani, M Lin, X Zhang… - Nature, 2023 - nature.com
Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …
Approved antiviral drugs over the past 50 years
E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …
categorized into 13 functional groups have been formally approved for the treatment of the …
T‐cell‐mimicking nanoparticles can neutralize HIV infectivity
To improve human immunodeficiency virus (HIV) treatment and prevention, therapeutic
strategies that can provide effective and broad‐spectrum neutralization against viral …
strategies that can provide effective and broad‐spectrum neutralization against viral …
Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development
L Imamovic, MOA Sommer - Science translational medicine, 2013 - science.org
New drug deployment strategies are imperative to address the problem of drug resistance,
which is limiting the management of infectious diseases and cancers. We evolved resistance …
which is limiting the management of infectious diseases and cancers. We evolved resistance …
CD4+ count–guided interruption of antiretroviral treatment
Strategies for Management of … - … England Journal of …, 2006 - Mass Medical Soc
Background Despite declines in morbidity and mortality with the use of combination
antiretroviral therapy, its effectiveness is limited by adverse events, problems with …
antiretroviral therapy, its effectiveness is limited by adverse events, problems with …
[HTML][HTML] Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial
MC Choudhary, KW Chew, R Deo, JP Flynn… - Nature …, 2022 - nature.com
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have
been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 …
been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 …
Point-of-care diagnostics for global health
P Yager, GJ Domingo, J Gerdes - Annu. Rev. Biomed. Eng., 2008 - annualreviews.org
Biomedical engineers have traditionally developed technologies in response to the needs of
the developed world's medical community. As a result, the diagnostic systems on which they …
the developed world's medical community. As a result, the diagnostic systems on which they …
Hepatitis B virus resistance to nucleos (t) ide analogues
F Zoulim, S Locarnini - Gastroenterology, 2009 - Elsevier
Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …